← Wiki Index / Microbiology & Immunology / T Helper 9 Cell
🦠 Microbiology & Immunology

T Helper 9 Cell

T helper 9 cells (TH9 cells) are a specialized effector CD4+ T-lymphocyte subset differentiated by combined transforming growth factor-beta (TGF-β) and interleukin-4 (IL-4) signaling via transcription factors PU.1, IRF4, and STAT6 that secrete interleukin-9 (IL-9) to drive helminth expulsion, allergic inflammation, and anti-tumor immunity.

T helper 9 cells (TH9 cells) are a specialized effector lineage of CD4+ helper T lymphocytes programmed by the synergistic action of transforming growth factor-beta (TGF-β) and interleukin-4 (IL-4) to secrete copious quantities of the pleiotropic γc-family cytokine interleukin-9 (IL-9) alongside IL-10 and IL-21, without producing the classical TH2 cytokines IL-4, IL-5, or IL-13. Governed by a collaborative transcriptional network anchored by the ETS-family pioneer factor PU.1 (SPI1), interferon regulatory factor 4 (IRF4), STAT6, BATF, and Smad2/3/4—coupled with active suppression of Foxp3 and T-bet—TH9 cells localize to mucosal barrier tissues of the lungs, gastrointestinal tract, and skin. At these interfaces, TH9-derived IL-9 orchestrates mast-cell recruitment and protease maturation, goblet-cell mucin hyperplasia, and smooth-muscle hypercontractility to expel parasitic helminths, while also driving allergic asthma, atopic dermatitis, ulcerative colitis, and potent granzyme- and mast-cell-dependent anti-tumor immunity against solid malignancies such as melanoma.

Lineage Discovery and Dual Cytokine Differentiation Circuitry

Reclassification from a TH2 Subpopulation to an Independent Lineage (2008–2010)

For two decades following the cloning of interleukin-9 (IL-9) in 1988–1989 by Jacques Van Snick and Jean-Christophe Renauld as a T-cell and mast-cell growth factor (originally termed P40), IL-9 was classified simply as a secondary effector cytokine of conventional TH2 cells. In 2008, two independent landmark studies by Vijay K. Kuchroo and Mohamed Oukka and by Brigitta Stockinger and Marc Veldhoen demonstrated that IL-9-producing CD4+ T cells represent a distinct effector lineage (TH9) induced by combining two cytokines that individually specify alternative fates:

  • TGF-β Alone vs. TGF-β + IL-4: When naive CD4+ T cells are stimulated through the T-cell receptor (TCR) in the presence of TGF-β alone, Smad2/3 activation induces the transcription factor Foxp3, generating immunosuppressive peripheral regulatory T cells (iTreg). Conversely, IL-4 alone activates STAT6 and GATA3 to generate classical TH2 cells. When TGF-β and IL-4 are present simultaneously, IL-4-activated STAT6 recruits histone deacetylases to silence TGF-β-induced Foxp3 expression, while TGF-β redirects the TH2 program away from IL-4/IL-5/IL-13 synthesis toward high-level transcription of the Il9 locus.
  • TH2-to-TH9 Plasticity: In addition to de novo differentiation from naive CD4+ precursors, already polarized TH2 cells exposed to elevated tissue TGF-β during chronic airway remodeling can reprogram directly into Foxp3−IL-4−IL-9+ TH9 cells.

Transcriptional Architecture: PU.1, IRF4, STAT6, BATF, and FoxO1

Unlike TH1 (T-bet), TH2 (GATA3), TH17 (RORγt), or follicular helper T cells (Bcl-6), TH9 differentiation is not governed by a single solitary master regulator, but by a multi-module transcription factorosome assembled across conserved non-coding sequences (CNS1, the Il9 promoter; CNS0 and CNS2 enhancers; and the CNS-25 super-enhancer) of the Il9 gene:

  1. The TGF-β–PU.1 Chromatin Remodeling Module: As demonstrated by Mark H. Kaplan and colleagues (2010), TGF-β signaling via Smad2/3/4 and TAK1-dependent HIF-1α induces the ETS-family transcription factor PU.1 (encoded by SPI1) and the E-protein inhibitor Id3. PU.1 binds directly to the Il9 promoter (CNS1), where it serves as a chromatin switch: PU.1 physically sequesters GATA3 away from the Il4, Il5, and Il13 loci (extinguishing the TH2 program) while recruiting the histone acetyltransferases GCN5 and PCAF to acetylate histone H3 (H3K9ac/H3K27ac) across the Il9 promoter.
  2. The IL-4–STAT6–IRF4–BATF Enhancer Module: IL-4 receptor engagement activates JAK1/JAK3 and phosphorylates STAT6, which induces IRF4, BATF, and cytoplasmic/nuclear GATA3. IRF4 and BATF form cooperative heterodimers with AP-1 (JunB) and Smad3 at the Il9 promoter and CNS-25 enhancer to drive RNA polymerase II transcription.
  3. Costimulatory Super-Enhancers (OX40, TL1A, GITR, and Notch): TH9 expansion and Il9 transcription are amplified by tumor necrosis factor receptor superfamily (TNFRSF) costimulation and metabolic sensors:
    • OX40 (CD134) Ligation by OX40L: Activates TRAF6 and the non-canonical NF-κB pathway (RelB–p52 heterodimers), which binds the Il9 promoter to trigger robust, selective TH9 differentiation even under low cytokine concentrations.
    • TL1A (TNFSF15)–DR3 and IL-1β–NF-κB: Synergize with IL-2–STAT5 and PI3K–Akt–mTORC1–FoxO1/IRF8 signaling to open Il9 super-enhancers, whereas Bcl-6 (induced by IL-21) competes directly with STAT5 at the Il9 locus to restrain excessive TH9 polarization.
Parameter / FeatureT Helper 9 (TH9) CellT Helper 2 (TH2) CellT Helper 22 (TH22) CellInduced Regulatory T (iTreg) Cell
Polarizing CytokinesTGF-β + IL-4 (amplified by IL-2, TL1A, OX40L, TSLP, IL-1β)IL-4 (amplified by TSLP, IL-25, IL-33)IL-6 + TNF-α (plus IL-1β and AhR ligands; inhibited by TGF-β)TGF-β + IL-2 (plus all-trans retinoic acid)
Core Transcription FactorsPU.1 (SPI1), IRF4, STAT6, BATF, Smad2/3, FoxO1, RelB–p52, HIF-1αGATA3, STAT6, STAT5, IRF4, c-MafAhR, STAT3, BNC2, FOXO4, T-betlow (RORγt−/low)Foxp3, Smad2/3, STAT5, Helios−
Signature Secreted CytokinesIL-9high, IL-10 (non-suppressive in TH9 context), IL-21, Granzyme BIL-4, IL-5, IL-13, amphiregulinIL-22, TNF-α, IL-13, FGFs (IL-17A−, IFN-γ−)IL-10, TGF-β, IL-35
Homing Chemokine ReceptorsCCR4+, CCR8+, CCR6+/−, CXCR3−CCR4+, CCR8+, CRTH2+ (PTGDR2)CCR10+, CCR6+, CCR4+ (CLA+ skin-homing)CCR4+, CCR6+, GPR15+ (colonic mucosa)
Primary Biological FunctionsMast-cell expansion, helminth expulsion, allergic asthma, anti-melanoma immunityIgE class switching, eosinophil recruitment, alternative macrophage (M2) polarizationKeratinocyte & enterocyte β-defensin secretion and epithelial wound repairMucosal peripheral tolerance to commensal microbiota and dietary antigens

Interleukin-9 Receptor Signaling and Mucosal Barrier Physiology

The Heterodimeric IL-9R–γc Complex and JAK1/JAK3 Cascade

Secreted IL-9 (a 14-kDa core four-α-helix bundle glycoprotein heavily glycosylated to ~32–39 kDa) binds to the heterodimeric IL-9 receptor, composed of the ligand-specific IL-9Rα chain (CD129) and the shared common gamma chain (γc / CD132) also utilized by IL-2, IL-4, IL-7, IL-15, and IL-21. Receptor cross-linking brings JAK1 (constitutively associated with IL-9Rα) and JAK3 (associated with γc) into proximity, phosphorylating a single conserved tyrosine residue (Tyr116 in human IL-9Rα) that serves as a docking site for three parallel signaling cascades: STAT1, STAT3, and STAT5 heterodimers and homodimers, alongside insulin receptor substrate-1/2 (IRS-1/IRS-2)–PI3K–Akt and MAPK/ERK.

Anti-Helminth Immunity and the Mast Cell–ILC2 Amplifying Loop

IL-9Rα is expressed selectively on mucosal mast cells, group 2 innate lymphoid cells (ILC2s), airway and intestinal goblet cells, smooth muscle cells, and subsets of B cells and dendritic cells:

  • Rapid Expulsion of Gastrointestinal Nematodes: During infection with parasitic roundworms such as Nippostrongylus brasiliensis, Trichuris muris, or Trichinella spiralis, TH9 cells expand early in mesenteric lymph nodes and the intestinal lamina propria prior to peak TH2 accumulation. TH9-derived IL-9 binds IL-9R on mucosal mast cells (synergizing with stem cell factor / c-Kit ligand) to induce rapid mastocytosis and transcription of mast-cell chymases and tryptases (mMCP-1, mMCP-2, mMCP-4) alongside high-affinity IgE receptor (FcεRIα) expression. Simultaneously, IL-9 stimulates epithelial goblet-cell hyperplasia (MUC2 and MUC5AC mucin hypersecretion) and smooth-muscle peristaltic contractility—the classic "weep and sweep" response that physically dislodges worms from the intestinal mucosa.
  • Cross-Talk with Group 2 Innate Lymphoid Cells (ILC2s): Epithelial alarmins (IL-33, IL-25, and TSLP) released upon tissue damage stimulate mucosal TH9 cells and ILC2s. TH9-derived IL-9 acts as an autocrine and paracrine survival factor for ILC2s via STAT5-induced Bcl-3 and Bcl-xL, amplifying ILC2 secretion of IL-5, IL-13, and amphiregulin to coordinate eosinophil recruitment and epithelial barrier restitution.

Pathogenic Roles in Allergy and IBD vs. Anti-Tumor Immunotherapy

Allergic Airway Inflammation and Ulcerative Colitis

When directed against innocuous environmental aeroallergens (such as house dust mite Der p 1 or Aspergillus spores), TH9 responses become pathogenic drivers of allergic asthma and atopic dermatitis. In asthmatic airways, TH9 cells clustering in peribronchial cuffs secrete IL-9 that drives intraepithelial mast-cell accumulation, bronchial goblet-cell metaplasia, subepithelial collagen deposition, and methacholine-induced airway hyperresponsiveness. In the gastrointestinal tract, Markus F. Neurath and colleagues (2014) demonstrated that lamina propria TH9 cells are markedly expanded in patients with ulcerative colitis: PU.1+ TH9-derived IL-9 acts directly on intestinal epithelial cells via STAT5 to downregulate tight-junction proteins (claudin-1, occludin, and ZO-1), impairing mucosal wound healing and allowing luminal bacteria from the human microbiome to translocate across the breached epithelial barrier.

Potent Anti-Melanoma and Solid Tumor Immunity

Paradoxically, despite their pro-allergic profile in barrier tissues, adoptively transferred tumor-specific TH9 cells exhibit superior anti-tumor efficacy compared to TH1, TH17, or TH2 cells in preclinical models of melanoma and lung adenocarcinoma—a discovery pioneered by Thomas S. Kupper, Patrick Hwu, and Qing Yi (2012–2018):

  1. Direct Granzyme-Mediated Cytolysis: Stimulated by tumor-microenvironment TGF-β, IL-4, and IL-1β, TH9 cells upregulate the transcription factor Eomesodermin (Eomes) and secrete high levels of Granzyme B, Granzyme A, and Perforin, enabling direct cytolytic killing of MHC-II+ melanoma cells akin to CD4+ cytotoxic T cells.
  2. CCL20–CCR6 Dendritic Cell and CD8+ CTL Recruitment: TH9-derived IL-9 and IL-21 stimulate tumor-infiltrating mast cells and lung/skin stromal cells to secrete the chemokine CCL20. CCL20 recruits CCR6+CD8α+/CD103+ cross-presenting dendritic cells (cDC1s) into the tumor bed, which travel to draining lymph nodes along fibroblastic reticular cell conduits to prime tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) via cross-presentation and stimulate IFN-γ production.
  3. Resistance to Exhaustion and Hyperproliferative Persistence: Unlike TH1 cells—which rapidly acquire terminal exhaustion markers (PD-1highTIM-3+LAG-3+) inside solid tumors—TH9 cells activated via IL-1β–IRF1–IL-21 and PU.1–TRAF6–NF-κB display a hyperproliferative, non-exhausted cytolytic phenotype that persists long-term in vivo, making ex vivo-polarized TH9 cells and chimeric antigen receptor (CAR-TH9) lymphocytes promising candidates for solid-tumor adoptive cell therapy.

Frequently Asked Questions

How does TGF-β switch TH2 cells into TH9 cells instead of regulatory T cells?

When naive CD4+ T cells encounter TGF-β alone, Smad2/3 signaling induces the transcription factor Foxp3, committing the cell to an immunosuppressive regulatory T-cell (iTreg) fate. However, when IL-4 is present alongside TGF-β, IL-4-activated STAT6 binds to the Foxp3 locus and recruits histone deacetylases that silence Foxp3 expression. Simultaneously, TGF-β induces the ETS transcription factor PU.1 (SPI1), which physically sequesters GATA3 away from classical TH2 genes (Il4, Il5, Il13) and recruits histone acetyltransferases (GCN5/PCAF) to open the Il9 promoter, where PU.1 cooperates with IL-4-induced IRF4, BATF, and STAT6 to drive selective high-level IL-9 transcription.

Why are TH9 cells effective at eradicating solid tumors like melanoma?

TH9 cells combat solid tumors through three synergistic mechanisms. First, tumor-infiltrating TH9 cells secrete IL-9, which activates tissue mast cells and induces epithelial and stromal cells to release the chemokine CCL20, recruiting CCR6+ dendritic cells and CD8+ cytotoxic T lymphocytes into the tumor bed. Second, TH9 cells co-stimulated by IL-1β and OX40 express Granzyme B and IL-21, allowing them to directly lyse tumor cells and sustain CD8+ T-cell and natural killer (NK) cell cytotoxicity. Third, PU.1- and TRAF6-driven NF-κB signaling protects TH9 cells from early T-cell exhaustion, allowing them to proliferate and persist inside hostile tumor microenvironments.

What is the physiological role of TH9 cells in ulcerative colitis?

In ulcerative colitis, lamina propria CD4+ T cells express elevated levels of PU.1 and IL-9. Secreted IL-9 binds IL-9R on intestinal epithelial cells and activates STAT5, which downregulates epithelial tight-junction proteins (claudin-1 and occludin) and inhibits enterocyte proliferation at mucosal ulcer margins. This disruption of epithelial barrier repair increases paracellular permeability, allowing luminal bacteria and endotoxins to penetrate into the lamina propria and perpetuate chronic mucosal inflammation.

References

  1. Veldhoen, M., Uyttenhove, C., van Snick, J., Helmby, H., Westendorf, A., Buer, J., Martin, B., Wilhelm, C., & Stockinger, B. (2008). "Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9–producing subset." Nature Immunology, 9(12), 1341–1346. https://doi.org/10.1038/ni.1659
  2. Dardalhon, V., Awasthi, A., Kwon, H., Galileos, G., Gao, W., Sobel, R. A., Mitsdoerffer, M., Strom, T. B., Elyaman, W., Ho, I.-C., Khoury, S., Oukka, M., & Kuchroo, V. K. (2008). "IL-4 inhibits TGF-β-induced Foxp3+ T cells and, together with TGF-β, generates IL-9+ IL-10+ Foxp3− effector T cells." Nature Immunology, 9(12), 1347–1355. https://doi.org/10.1038/ni.1677
  3. Chang, H.-C., Sehra, S., Goswami, R., Yao, W., Yu, Q., Stritesky, G. L., Jabeen, R., McKinley, C., Ahyi, A.-N., Han, L., Nguyen, E. T., Robertson, M. J., Perumal, N. B., Tepper, R. S., Nutt, S. L., & Kaplan, M. H. (2010). "The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation." Nature Immunology, 11(6), 527–534. https://doi.org/10.1038/ni.1867
  4. Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., Clark, R. A., & Kupper, T. S. (2012). "Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells." Nature Medicine, 18(8), 1248–1253. https://doi.org/10.1038/nm.2856
🧬 Support Open Science
Explore interactive science games on LowKey Games or browse scientific apparel & accessories in the CRV Science Shop.
💡 Spot an inaccuracy or have primary literature to expand this article?
Submit a citation or revision note using your shared CRV Science / LowKey Games profile ID.
Suggest Revision